Incidence of distal intestinal obstruction syndrome in cystic fibrosis.
A variety of intestinal complications, including constipation, abdominal pain, palpable cecal masses, intestinal obstruction, intussusception, and volvulus, have been observed beyond the neonatal period in patients with cystic fibrosis (CF). In a retrospective chart review of 63 patients with CF, we found evidence of one or more of these complications in 26 patients (41.3%). The incidence of intestinal complications was not related to overall disease severity, pulmonary exacerbations, history of meconium ileus at birth, or dose or type of pancreatic enzyme replacement. There was no change in the incidence of intestinal complications after patients switched to a pH-sensitive enteric-coated microsphere enzyme preparation.
D000293:Adolescent; D002648:Child; D003550:Cystic Fibrosis / Q000150:complications* / Q000628:therapy; D006801:Humans; D007415:Intestinal Obstruction / Q000209:etiology*; D008049:Lipase / Q000627:therapeutic use; D010184:Pancreatic Extracts / Q000627:therapeutic use; D010194:Pancreatin / Q000627:therapeutic use; D020799:Pancrelipase; D012189:Retrospective Studies
D010184:Pancreatic Extracts; D020799:Pancrelipase; D010194:Pancreatin; D008049:Lipase